Hyphen BioMed and Aniara Corporation bringing you cost effective, innovative, quality laboratory tools in compliance with recent scientific understandings in Haemostasis/Thrombosis & Fibrinolysis.

The French company Hyphen BioMed is a well-known European company in the field of biochemical’s, immunological, in vitro research and diagnostic reagents for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immune disorders associated with thrombosis diseases. Hyphen BioMed is expanding rapidly, and one of its major goals is to be introduced on the North American market through its close partnership with Aniara Corporation. Aniara is dedicated to introduce new laboratory tools and diagnostic methods to clinical laboratories, academic research institutes, biotech and pharmaceutical companies in North America. Hyphen BioMed and Aniara are looking forward to establish a major technical and scientific partnership with any organization involved in clinical diagnosis, medical research or drug development, especially for new drugs designed for fighting thrombosis diseases or managing bleeding risk, as well as for monitoring therapies developed for managing these complications. Hyphen BioMed and Aniara are committed to listen to new clinical and research requests, and combine their in-depth experience and their understanding of laboratory requirements. In order to offer the most updated laboratory methods and in vitro testing tools to today’s laboratories and researchers.

Hyphen BioMed & Aniara listen and understand the needs of the laboratories and researchers:

In the last couple of years, a very large product range from Hyphen BioMed (including 510K products) has been introduced to North America and is continuously expanding. The clinical excusive distributor of Hyphen BioMed, Aniara Corporation provides ready to use kits concerning clotting (Hemoclot Product Line), chromogenic (BIOPHEN Product Line) and immunoassays (Zymutest/ELISARA Product Line) for most of the Haemostasis and Thrombosis factors, and their metabolites. Hyphen BioMed has developed a full range of innovative kits for monitoring anti-thrombotic drugs such as heparins and their derivatives, or direct thrombin inhibitors.

An important characteristic of Hyphen BioMed and Aniara is the strong relationship with academic research and new technological developments, through direct partnerships. Aniara, continually research the market needs and helps to design new products for the different kinds of applications based on clinical demands. As the exclusive clinical distributor in North America, Aniara remains very close to the major users of Hyphen BioMed’s products, and continuously analyses evolution of laboratory needs, and new trends. This survey helps in defining the specification of the products required for meeting these market requests. Hyphen BioMed, with its vast experience is able to develop the expected product. Making it available to the market rapidly, using the shortest development time between analysis of needs, product development and manufacture of kit.

Remaining at the forefront of innovation in this field, new assays or new concepts are being offered to the healthcare, scientific, and biotech/pharmaceutical communities at a rapid pace. For example, the quantitative clotting assay for factor V-Leiden, the measurement of procoagulant activity of microparticles released in blood. This can be the cause or the consequence of a disease. A new approach for testing heparin dependent antibodies, involved in the development of Heparin Induced thrombocytopenia (HIT), which is of special clinical relevance in today’s clinical laboratories.

What differentiates Hyphen BioMed from similar companies:

Hyphen BioMed’s expertise relies primarily on its knowledge and experience of protein biochemistry, preparation of enzymes and immune-technology, especially concerning factors involved in Haemostasis/Thrombosis and Fibrinolysis, and regulation of their mechanisms. All the proteins involved in those mechanisms are currently being purified in the highest purity grade available, and are of special relevance for in vitro studies aimed to investigate and to understand the various mechanisms implicated. The proteins are usually extracted from high quality human or bovine citrated plasmas, non-activated, and which are only used for these modern preparations. The most modern laboratory separation tools to date are used, including salt fractionation, ion exchange chromatographies, affinity chromatographies, gel permeation, etc. As a result, proteins obtained are very homogeneous, producing generally only one band on SDS Page, non-denatured and non-activated. Hyphen BioMed can therefore offer the highest activity to protein ratio available on the market. Hyphen BioMed proteins are then the preparations of choice for any research or fundamental study on Haemostasis mechanisms. Hyphen BioMed proteins are also very useful for designing unique assays developed with these purified fractions, as they offer high specificity and reactivity, associated with an increase reagent stability following reconstitution.

Hyphen BioMed’s highly purified proteins are also used in the preparation of Haemostasis enzymes, such as Factor Xa, IXa, Activated Protein C (APC) or Thrombin, very homogeneous and fully functional. These enzymes are of a special relevance for developing assays for Haemostasis cofactors or inhibitors. Due to Hyphen BioMed’s high purity grade, an excellent stability is obtained for reagents prepared with these enzymes.

This offer of biochemicals is completed by a full range of chromogenic substrates specific for these various enzymatic activities, involved in Haemostasis. The BIOPHEN® line of chromogenic substrates is a new line of generic chromogenic substrates which allow testing enzymes involved in coagulation and Fibrinolysis. These substrates offer prolonged stability following reconstitution. Aniara can provide substrates in bulk format and for industrial use. Methods have been developed for Factor Xa and Factor IIa assays. We can validate your methods with our reagents – at our lab in France.

Proteins are also used for preparing polyclonal or monoclonal antibodies, very reactive and with high affinity for their target antigen or their specific epitope. These basic immunological reagents are then useful for designing highly sensitive and specific immunoassays. For Example Elisa’s or latex based photometric assays for Haemostasis/Thrombosis factors, identification of conformational changes on proteins. Also, for measuring analytes or metabolized products, which are of relevant usefulness for diagnosing circulatory diseases, or monitoring their specific therapies.

Another application of purified proteins is the development of immune-assays for auto-antibodies targeted to Haemostasis proteins, and especially those which are Phospholipid or Heparin dependent. Hyphen BioMed is very active in this field, and offers a full line of well characterized, specific and sensitive assays for antibodies Phospholipid dependent or targeted to Phospholipid cofactors, or Heparin dependent antibodies. Quality and usefulness of these assays for auto-antibodies is widely acknowledged by scientific community and by a large network of clinical applications, worldwide. With an optimized sensitivity non specific interactions are reduced to the lowest level, and only the “true” auto-antibodies are measured.
In addition to the internal use of all these biochemical’s and immune-chemicals, HYPHEN BioMed offers these products for research use. This line of research products meets many of the needs of clinical and epidemiological research, and more especially those required by drug discovery. Hyphen BioMed can also assist in developing custom made assays based on clients needs. Hyphen BioMed and Aniara listen to the client’s need and develop and validate the method in Hyphen BioMed’s advanced laboratory in France. Hyphen BioMed will then send the reagents or prototype kit with a recommended method to the client for final validation. This saves time and money for implementing a new assay in a client’s facility.

Clinical validation of the assays and defining novel applications:

Once the assays have been developed, a close collaboration with Aniara allows for timely validation of the applications with the FDA and Canadian registrations as required. According to the various potential applications, Aniara has established close partnerships with many clinical laboratories, research institutes and biotech/pharmaceutical industries in North America, investigating the assay performances, defining its usefulness and conditions of use. This is an interactive partnership which allows us to continuously revisit the assay concept in order to better develop the assay to the laboratory needs. This concept provides a win-win relationship, in which the technological solution offered is the result of understanding the laboratory needs, and the product concept through our experience and industry know-how.

Hyphen BioMed Market Introduction to North America with Aniara Corporation:

The cornerstone for our launch in North America is based on product quality, service efficiency and cost control, all relating back to our win-win philosophy. Hyphen BioMed has complete control of the manufacturing process (raw materials, active principles and assays are fully designed and produced by Hyphen BioMed, and specifically conceived for meeting the final product specifications). The exclusive clinical partnership between Hyphen BioMed and Aniara Corporation aims to introduce the full line of products and services in North America, and to become a major partner in the field of Thrombosis and Haemostasis sciences, and for supporting drug discoveries in this field. Aniara Corporation’s head office and warehousing facility is based outside Cincinnati, OH. Aniara Corporation is bringing in a new look of marketing and sales of Hyphen BioMed’s products. Aniara believes in making all our information easy accessible, by making all relevant information available on its website www.aniara.com. There you can find Product catalogues, Package inserts, MSDS sheets, instrument applications, etc. Aniara is aware of the continuous budget pressures and dead lines, hence all prices are provided directly on the website. The website also offers real-time purchasing of products with credit cards or invoicing and the on-line order desk is available 24/7. Aniara believes in giving back to the community, and have established a Coagulation Lab Technologist award in the amount of $1000 that is given out every year by its peers, reaffirming its win-win philosophy. They have also established an annual research grant in the amount of $5000. The Aniara Grant is awarded at ASH every year and the award recipient is selected by a board of volunteers comprised of international fellow doctors. Aniara is a strong believer in academic research. Aniara has established an Academic Research program. If qualified the person will receive 25% discount on all Hyphen BioMed products. Quality, Innovation, Service and control of expenses are our commitments.

Hyphen BioMed and Aniara Corporation constantly rely on new technologies and breakthroughs in order to assist in laboratory work optimization, standardization and making our products more automatable. Our philosophy is focused on the introduction of new technologies usable on most of the automated systems available. Hyphen BioMed and Aniara offers you a high quality product, with attentive service at a significantly lower price. Hyphen BioMed and Aniara Corporations is looking forward in establishing a win-win partnership with you and your operations.

Dr. Jean Amiral
Hyphen BioMed